AMPH Q4 2025 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$183M-1.8% YoY

Gross Profit

$86M46.8% margin

Operating Income

$36M19.4% margin

Net Income

$24M13.3% margin

EPS (Diluted)

$0.51

QoQ Revenue Growth

-4.6%

Cash Flow

Operating Cash Flow

-$123M

Free Cash Flow

-$97M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$840M

Stockholders' Equity

$789M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$183M	$187M	-1.8%
Gross Profit	$86M	$87M	-1.1%
Operating Income	$36M	$45M	-21.1%
Net Income	$24M	$38M	-35.7%

Revenue Segments

Epinephrine

$36M100%

Geographic Segments

UNITED STATES

$172M100%